Erik A. Lippa - Concepedia

Author

Erik A. Lippa

United States Military Academy

Also Known As

ERIK A. LIPPA, Erik A Lippa, Erik A. Lippa, Erik Lippa

Publications

529

Citations

H-Index

Concepts

All Affiliations

United States Military Academy

About

Erik A. Lippa is an author at United States Military Academy specializing in medicine, pharmacotherapy, and ophthalmology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	354
2	Natural Sciences	1	1	47
3	Anesthesia	1	1	47
4	Biochemistry	1	1	47
5	Chemical Biology	1	1	47

Erik A. Lippa

Publications

513

Citations

H-Index

Page 1

	Year	Citations
Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor Erik A. Lippa Archives of Ophthalmology	1992	130
The Application of Multiple Quality-of-Life Instruments in Individuals with Mild-to-Moderate Psoriasis Michael B. Nichol, Jane E. Margolies, Erik A. Lippa, PharmacoEconomics Multiple Quality-of-life InstrumentsQuality Of LifeLife AssessmentPsoriatic ArthritisClinical Dermatology	1996	97
Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatin Alan M. Laties, Charles L. Shear, Erik A. Lippa, The American Journal of Cardiology Ocular DiseaseHuman LensExpanded Clinical EvaluationOphthalmologyMedicine	1991	79
MK-507 versus Sezolamide Erik A. Lippa, Joel S. Schuman, Eve J. Higginbotham, Ophthalmology Medicinal ChemistryMedicineMechanism Of ActionPharmacotherapyDrug Development	1991	71
The Use of Dorzolamide and Pilocarpine as Adjunctive Therapy to Timolol in Patients with Elevated Intraocular Pressure Ellen R. Strahlman, Roger Vogel, Robert Tipping, Ophthalmology HypertensionElevated Intraocular PressureAdjunctive TherapyOcular DiseaseOphthalmology	1996	60
Local Tolerance and Activity of MK-927, a Novel Topical Carbonic Anhydrase Inhibitor Erik A. Lippa Archives of Ophthalmology HypertensionOcular DiseasePharmaceutical SciencePharmacotherapyOcular Surface Physiology	1988	47
Assessment of systemic effects of different ophthalmic β-blockers in healthy volunteers Karin Bauer, Françoise Brunner‐Ferber, Linda M. Distlerath, Clinical Pharmacology & Therapeutics	1991	15
Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects Thierry Buclin, Jérôme Biollaz, Erik A. Lippa, Clinical Pharmacology & Therapeutics	1991	14

Page 1